• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ANVS

    Annovis Bio Inc.

    Subscribe to $ANVS
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

    IPO Year: 2020

    Exchange: AMEX

    Website: annovisbio.com

    Recent Analyst Ratings for Annovis Bio Inc.

    DatePrice TargetRatingAnalyst
    2/10/2025Buy → Hold
    D. Boral Capital
    10/25/2024$25.00Hold → Buy
    Maxim Group
    12/29/2023$36.00Buy
    Canaccord Genuity
    7/7/2021$45.00 → $150.00Buy
    Maxim Group
    See more ratings

    Annovis Bio Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Annovis Bio Inc.

      DEFA14A - Annovis Bio, Inc. (0001477845) (Filer)

      5/1/25 5:20:16 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Annovis Bio Inc.

      DEF 14A - Annovis Bio, Inc. (0001477845) (Filer)

      4/30/25 5:20:39 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      3/27/25 4:35:31 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Annovis Bio Inc.

      10-K - Annovis Bio, Inc. (0001477845) (Filer)

      3/21/25 5:15:59 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      3/21/25 5:10:46 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      2/5/25 8:08:10 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      2/4/25 9:18:31 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Annovis Bio Inc.

      424B5 - Annovis Bio, Inc. (0001477845) (Filer)

      2/4/25 6:01:57 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Annovis Bio Inc.

      424B5 - Annovis Bio, Inc. (0001477845) (Filer)

      2/3/25 6:00:48 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      12/11/24 4:25:34 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Annovis Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

      SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

      11/28/23 4:05:14 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Annovis Bio Inc.

      SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

      11/8/23 7:02:36 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Annovis Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Annovis Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Annovis Bio downgraded by D. Boral Capital

      D. Boral Capital downgraded Annovis Bio from Buy to Hold

      2/10/25 8:18:59 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio upgraded by Maxim Group with a new price target

      Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

      10/25/24 7:56:01 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Annovis Bio with a new price target

      Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00

      12/29/23 7:03:31 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on Annovis Bio with a new price target

      Maxim Group reiterated coverage of Annovis Bio with a rating of Buy and set a new price target of $150.00 from $45.00 previously

      7/7/21 9:19:55 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

      MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the "Notice") from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholde

      3/27/25 4:30:00 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

      MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. "We are at a pivotal moment in our company's journey as we have entered the late clinical stages for both Alzheimer's and Parkinson's. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications," commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. "A

      3/25/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results. In 2024, Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing buntanetap's ability to improve cognition in AD and PD patients, as well as motor function in PD patients. Building on this

      3/21/25 5:05:30 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

      MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer's & Parkinson's Drug Development Summit happening on March 18-20 in Boston, MA. "This meeting represents an important opportunity to advance our understanding of the next-generation treatment for neurodegenerative diseases, which we have long argued are too complex for a narrow therapeutic approach. Research must shift to a more holistic solution, addressing multiple neurotoxic proteins and

      3/11/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis to Host Patients' Live Forum on February 27, 2025

      MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE:ANVS)  ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will host a live webcast where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families about the Company's clinical trials and future plans. Webcast Details Event: Annovis Patients' Forum: Your Questions AnsweredDate: February 27, 2025Time: 4:30 PM ESTRegistration: Click here to register During the webcast, Dr. Maccecchini will provide updates on the on

      2/19/25 8:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

      MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. Presentation details Date: February 11, 2025Time: 12:40 – 1:10 p.m. ET Attendees can access the live presentation through the conference's virtual platform. Dr. Maccecchini will discuss the Company's latest advancements, highlighting the progress of the

      2/7/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

      MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a co

      2/5/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

      MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share and associated warrant. The warrants have an exercise price of $5.00 per share and are immediately exercisable upon issuance for a period of five years following the date of

      2/4/25 4:31:00 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

      MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share. The warrants will have an exercise price of $5.00 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares

      2/3/25 6:22:46 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Annovis Bio Inc. Financials

    Live finance-specific insights

    See more
    • Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

      Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

      10/5/21 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Annovis Bio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

      MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

      11/7/24 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Andrew Walsh as Vice President Finance

      BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.  "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a

      12/1/23 7:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer

      TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres

      3/13/23 8:00:00 AM ET
      $ANVS
      $SFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance/Investors Services
      Finance
    • Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

      BERWYN, Penn., Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "This quarter, we have made significant advances in the clinical development of buntanetap as we began to dose patients in our Phase 3 trial for early Parkinson's Disease and received FDA author

      11/8/22 5:35:00 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

      BERWYN, Pa., Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.  Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative medicine company.  The company has also announced that Jeff McGroarty has stepped away from his role as Chief Financial Officer to pursue other interests.  Mr. McGroarty will assist in an orderly transition of his duties over the ne

      8/29/22 4:00:00 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

      Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, "we have made significant progress advancing buntanetap in Parkinson's disease and Alzheimer's disease this quarter. We received positive feedback from the U.S. Food and Drug Administration (FDA) for two Phase 3 clinical trials with buntanetap in early and late Parkinson's disease. As our clinical trials ad

      5/4/22 8:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Enhances Leadership Team with Two Senior Appointments

      Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the promotion of Cheng Fang, Ph.D., to Senior Vice President of Research & Development, as of January 1, 2022."We are all delighted to welcome Ms. Damiano to our diverse team of highly motivated industry expe

      1/10/22 8:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research

      Dr. Fang has authored 15 published papers including two on axonal transport and several on protein aggregationBerwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Cheng Fang, Ph.D., as its new Vice President of Research."I am excited to welcome Dr. Fang to Annovis Bio. Her knowledge of research in our field, as well as in general, is excellent," commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. "She will be instrumental in furthering our work on the mechanism of action of our drug

      5/18/21 8:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman

      Berwyn, Pennsylvania--(Newsfile Corp. - April 15, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Reid S. McCarthy to its Board of Directors and to the role of Audit Committee chairman, effective April 9, 2021.A specialist in bank, bond, and equity financings, McCarthy retired after serving from 2016 to 2019 as CFO of JJ Haines & Company, Inc., a $400 million revenue distribution company operating internationally. Previously, McCarthy provided CFO consulting services to several life sciences companies, served as CFO of Topaz Pharm

      4/15/21 7:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Annovis Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director White Mark K.

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:18:10 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mccarthy Reid

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:17:22 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Maccecchini Maria-Luisa gifted 30,000 shares, decreasing direct ownership by 3% to 1,068,459 units (SEC Form 4)

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:16:55 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoffman Michael B

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:16:18 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bruck Claudine

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:15:43 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • White Mark K. was granted 1,990 shares, increasing direct ownership by 3% to 61,167 units (SEC Form 4) (Amendment)

      4/A - Annovis Bio, Inc. (0001477845) (Issuer)

      11/22/23 4:27:49 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mccarthy Reid acquired 0 shares (SEC Form 4) (Amendment)

      4/A - Annovis Bio, Inc. (0001477845) (Issuer)

      11/22/23 4:24:29 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoffman Michael B was granted 163,880 shares (SEC Form 4) (Amendment)

      4/A - Annovis Bio, Inc. (0001477845) (Issuer)

      11/22/23 4:24:21 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maccecchini Maria-Luisa was granted 40,970 shares, increasing direct ownership by 4% to 1,098,459 units (SEC Form 4) (Amendment)

      4/A - Annovis Bio, Inc. (0001477845) (Issuer)

      11/22/23 4:23:15 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hagopian Henry Iii was granted 820 shares, increasing direct ownership by 82% to 1,820 units (SEC Form 4) (Amendment)

      4/A - Annovis Bio, Inc. (0001477845) (Issuer)

      11/22/23 4:21:13 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care